EUVIMEDEUVIMED entdecken
Metaanalyse

Abstract 8512: SGLT2 Inhibitors After Catheter Ablation for Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials with Reconstructed Kaplan-Meier Data

Ameer Awashra, Ahmed Emara, Elsayed Balbaa, Mohamed S Elgendy, Belal Hamed, Fathi Milhem, Abdalhakim Shubietah, Mohammed Mhanna, Mohammed Al-Sadawi

Circulation · 02.11.2026 · 154 (Suppl_1)

DOI: 10.1161/circ.154.suppl_1.8512 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Ameer Awashra und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atrial fibrillation (AF) recurrence after catheter ablation remains a major clinical challenge. Sodium-glucose cotransporter-2 (SGLT2) inhibitors may attenuate atrial remodeling and fibrosis, potentially improving post-ablation outcomes. We performed a systematic review and meta-analysis evaluating the efficacy of SGLT2 inhibitors after AF ablation.

Methods

We searched PubMed, Cochrane Library, Scopus, and Web of Science for randomized controlled trials (RCTs) comparing SGLT2 inhibitors versus control therapy in patients undergoing AF catheter ablation. Random-effects meta-analysis pooled dichotomous outcomes as risk ratios (RRs) and continuous outcomes as standardized mean differences (SMDs). Reconstructed individual patient data from Kaplan-Meier curves were analyzed using pooled Cox regression, time-varying hazard models, landmark analysis, and restricted mean survival time (RMST).

Results

Four RCTs (n = 452 patients) were included. Reconstructed patient-level analysis from 370 patients showed no significant overall reduction in AF recurrence (HR 0.73, 95% CI 0.48-1.11; P=0.14). However, landmark analysis after 30 days demonstrated significantly lower recurrence with SGLT2 inhibitors (HR 0.58, 95% CI 0.34-0.98; P=0.041). SGLT2 inhibitors significantly reduced late AF recurrence between 3 and 12 months compared with control therapy (13.2% vs. 26.0%; RR 0.49, 95% CI 0.29-0.82; P=0.006). No significant reduction was observed in early AF recurrence at 3 months (RR 0.50, 95% CI 0.10-2.53; P=0.40) or all-cause mortality. SGLT2 inhibitors significantly lowered NT-proBNP levels (SMD –0.59, 95% CI –0.88 to –0.29; P

Zitieren

APA

Awashra, A., Emara, A., Balbaa, E., Elgendy, M. S., Hamed, B., Milhem, F., Shubietah, A., Mhanna, M., & Al-Sadawi, M. (2026). Abstract 8512: SGLT2 Inhibitors After Catheter Ablation for Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials with Reconstructed Kaplan-Meier Data. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.8512

Vancouver

Awashra A, Emara A, Balbaa E, Elgendy MS, Hamed B, Milhem F, et al. Abstract 8512: SGLT2 Inhibitors After Catheter Ablation for Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials with Reconstructed Kaplan-Meier Data. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.8512

BibTeX
@article{Awashra2026,
  author = {Awashra, Ameer and Emara, Ahmed and Balbaa, Elsayed and Elgendy, Mohamed S and Hamed, Belal and Milhem, Fathi and Shubietah, Abdalhakim and Mhanna, Mohammed and Al-Sadawi, Mohammed},
  title = {Abstract 8512: SGLT2 Inhibitors After Catheter Ablation for Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials with Reconstructed Kaplan-Meier Data},
  journal = {Circulation},
  year = {2026},
  volume = {154},
  number = {Suppl_1},
  doi = {10.1161/circ.154.suppl_1.8512}
}
Kostenlos starten →